BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript

Core Viewpoint - The conference call for BridgeBio is set to discuss the company's future operating and financial performance, business plans, and strategic prospects [1]. Group 1 - The call may contain forward-looking statements regarding BridgeBio's future operations and financial performance [1]. - These statements are based on current expectations and assumptions that are subject to risks and uncertainties [1]. - The company will not update any forward-looking statements made during the call, except as required by law [1].